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ATPaseBreast Cancer Resistance Protein (BCRP/ABCG2) belongs to the superfamily of ATP binding cassette (ABC)
transporters. Characteristic of some of these transporter proteins is the transport of a variety of structurally
unrelated substances against a concentration gradient by using the energy of ATP hydrolysis. ABCG2 has been
found to confer multidrug resistance (MDR) in cancer cells. Several anticancer drugs have been identiﬁed as
ABCG2 substrates including mitoxantrone, etoposide and topotecan. As inhibition of the transporter is one of
the strategies to overcome MDR, we have synthesized and tested several 3-methoxy ﬂavones and investigated
them for their ABCG2 inhibition. Among these, pentamethyl quercetin (compound 4) and pentamethyl morin
(compound 5) were found to be ﬂuorescent and hence screened for their possible transport by ABCG2 using
confocal microscopy. This study showed that pentamethyl quercetin was far less accumulated in ABCG2 overex-
pressing MDCK BCRP cells as compared to MDCK sensitive cells, suggesting possible efﬂux of this compound by
ABCG2. Pentamethyl morin showed no visible difference in both cell lines. Based on this observation, we studied
several other ﬂuorescent 3-methoxy ﬂavones for their accumulation in ABCG2 overexpressing cells. To conﬁrm
the substrate or inhibitor nature of the tested compounds, these compoundswere further investigated by ATPase
assay. If stimulation of the transporter ATPase activity is detected, one can conclude that the compound is
probably a transported substrate. All compounds except pentamethyl morin (compound 5) and tetramethyl
quercetin (compound 6) were found to stimulate ATPase activity pointing to possible substrates despite being
potent inhibitors of ABCG2.
© 2014 Elsevier B.V. All rights reserved.1. Introduction
Flavonoids are a group of naturally occurring low molecular weight
polyphenolic compounds that recently has been the subject of consider-
able scientiﬁc and therapeutic interest. They are found in a wide variety
of plants and are present in fruits, roots, stems and ﬂowers. Several
beneﬁcial effects of ﬂavonoids on health are known and ﬂavonoids are
consumed in daily diets and in form of tea and wine [1,2]. Different
ﬂavonoids have been found to be useful as anti-inﬂammatory, antican-
cer, antidepressant, antiallergic, antiproliferative and antiangiogenic
agents. Also generally a lack of toxicity is associated with this class of
compounds [3]. Recently, ﬂavonoids have received great attention for
their inhibitory effect against ATP binding cassette (ABC) transporters;
hence we synthesized several ﬂavonoid analogs as ABCG2 inhibitors
and investigated them extensively.
Breast cancer resistance protein (BCRP/ABCG2) is the second
member of ABC transporter subfamily G and has been found to play
an important role in conferring multidrug resistance in tumor cells49 228 737929.and modulating the pharmacokinetic properties of drugs which are its
substrates. It is a half transporter with a molecular weight of 72 kDa
[4]. It has been proposed that, to function as an active transporter
ABCG2 needs to be at least homo- or heterodimerized or higher oligo-
merizations are necessary [5]. Until now, several substrates including
anticancer drugs such as mitoxantrone [6], topotecan [7], irinotecan
[8], etc. have been identiﬁed. A few ﬂavonoids like ﬂavopiridol [9] and
a sulfated conjugate of biochanin A [10] have also been shown to be
substrates of ABCG2. In the search for potent and selective inhibitors
of ABCG2, several efforts have been taken in the last decade. Recently
identiﬁed inhibitors of ABCG2 belong to different chemical classes
such as chalcones, chromones, ﬂavonoids, quinazolines etc. [11–14]
Several naturally occurring ﬂavonoids as well as few synthetic analogs
have been reported to be good inhibitors of ABCG2 [14–20].
Recently we studied several ﬂavones and benzoﬂavones with the
aim of ﬁnding new potent, selective and non-toxic inhibitors of ABCG2
[21]. In that study synthesis and biological investigation of these com-
pounds for their inhibitory effects against major ABC transporters
ABCG2, P-gp and MRP1 was reported. Among these compounds, it
was observed that ﬂavones bearing a methoxy group at position 3 of
the ﬂavone moiety showed ﬂuorescence at 460 nm when excited at a
wavelength of 355 nm. Fluorescence spectra of compounds 1–7 and
Fig. 1. Fluorescence spectra of 3-methoxyﬂavones 1–7 and Hoechst 33342.
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tin) and 5 (pentamethyl morin) were ﬁrst investigated for their accu-
mulation in ABCG2 overexpressing MDCK BCRP cells after 4 h
incubation by confocal microscopy. Accumulation of these compoundsTable 1
Structures and inhibitory potencies of selected 3-methoxy ﬂavones against ABCG2 obtained in
Compound Structure IC
1 1
2 7
3 1
4 0
5 5
6 0
7 3was compared to that in sensitive MDCK cells. After comparison of ﬂuo-
rescence of accumulated compounds in cells using confocal microscopy,
it was observed that compound 4 showed lower accumulation inMDCK
BCRP cells when compared to its accumulation in non ABCG2 overex-
pressing sensitive cells. Such effect was not observed for compound
5, suggesting that compound 4 could be a substrate of ABCG2 leading
to its efﬂux and thus lower accumulation. Based on these prelimi-
nary results, other 3-methoxy ﬂavones were then investigated for
their accumulation in ABCG2 overexpressing cells by measuring
their ﬂuorescence using a microplate reader. Most of the com-
pounds showed lower accumulation in ABCG2 overexpressing
cells and to further conﬁrm this effect, we carried out ATPase stud-
ies to test the substrate nature of selected 3-methoxy-ﬂavones. The
ATPase assay can be used to investigate interaction of compounds
with ABC transporters such as ABCG2 [22]. Structures of these com-
pounds and their inhibitory potencies against ABCG2 obtained in
Hoechst 33342 assay are given in Table 1. Selected compoundswere ad-
ditionally investigated for their cytotoxicity andwere found to have low
toxicity even in the higher micro-molar range. These compounds were
also investigated to test their ability to reverse the drug resistance for
anticancer/cytotoxic compounds. In summary we were able to ﬁnd
few very potent, selective and low toxic inhibitors of ABCG2.the Hoechst 33342 and pheophorbide A assays.
50 (μM, Hoechst 33342 assay) IC50 (μM, pheophorbide A assay)
.21 ± 0.12 1.28 ± 0.17
.74 ± 0.35 6.50 ± 0.58
.18 ± 0.29 1.34 ± 0.19
.82 ± 0.17 1.88 ± 0.24
.98 ± 0.45 5.94 ± 0.74
.54 ± 0.08 0.570 ± 0.093
.27 ± 0.15 3.89 ± 0.16
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2.1. Accumulation studies of compounds 4 and 5 by confocal microscopy
Confocal microscopy was used to investigate the accumulation of
ﬂuorescent compounds 4 and 5 in ABCG2 overexpressing MDCK BCRP
cells. For sample preparation, ﬁrst cells were harvested after reaching
a conﬂuence of 80–90% by gentle trypsination (0.05% trypsin/0.02%
EDTA) and then transferred to a 50 ml tube followed by centrifugation
(266 ×g, 4 °C, 4 min). The cell pellet obtained was resuspended in
fresh culture medium and the cell density was determined using a
CASY1 model TT cell counter device (Schaerfe System GmbH, Reutling-
en, Germany). Followed by another centrifugation, cells were washed
three times with KHB and seeded into 6 well tissue culture plates at a
density of approximately 200,000 cells per well in a volume of
2900 μl. Cells were incubated overnight and on the next day medium
was changed, and 100 μl of various test compounds was added to a
total volume of 3000 μl. Then the cells were further incubated for 4 h,
after which the medium was removed and cells were washed two
times with 1 ml PBS. After removing PBS, 1 ml of 3.7% formaldehyde
in PBS solution was added and the plate was kept aside for 5 min with
intermittent shaking. In the end, formaldehyde solution was removed
and coverslips were ﬁxed on the glass slide using ﬂuomount and dried
for 24 h at room temperature. For visualizing accumulated compounds
in cell samples, DAPI ﬁlter was used on a Nikon A1 confocal microscope
system. The results obtained for compounds 4 and 5 are depicted in
Fig. 2.2.2. Accumulation measurement using a microplate reader
To investigate the accumulation of compounds in MDCK BCRP cells
and sensitive cells by measuring their ﬂuorescence, cells were ﬁrst pre-
pared as described above. Cells were seeded into 96 well tissue cultureCompound MDCK BCRP
4
5
Fig. 2. Accumulation of ﬂavones 4 and 5 in MDCK BCRP andplates at a density of approximately 10,000 cells per well in a volume of
100 μl culturemedium. Cellswere incubated overnight, on next dayme-
dium was changed and 100 μl of various test compounds were added.
All test compounds had a ﬁnal concentration of 25 μM. Cells were incu-
bated with test compounds for 4 h, followed by measurement of ﬂuo-
rescence at an excitation wavelength of 355 nm and emission
wavelength of 460 nm. As the ﬂuorescence wavelengths of Hoechst
33342 overlap to that of compounds (excitation λ=355 nm and emis-
sion λ=460 nm) there was interference with the Hoechst 33342 ﬂuo-
rescence. As Hoechst 33342 shows almost no ﬂuorescence in the
absence of cells, blank readings were taken using only buffer solution
of the same volume along with Hoechst 33342 and test compounds.
This gave the ﬂuorescence of test compounds for each concentration.
This ﬂuorescence was then deducted from the ﬂuorescence obtained
for the with cells group. This allowed us to eliminate any ﬂuorescence
interference of these compounds. Additionally the ﬁtted top values
(corresponding to maximum ﬂuorescence at full inhibition) were com-
pared to those obtained with a non-ﬂuorescent standard inhibitor (XR
9577, Ko143) to ensure consistency of the subtraction procedure. This
problem was not observed in the case of pheophorbide A assay as
these compounds do not show any ﬂuorescence in excitation/emission
wavelengths range used for pheophorbide A assay. For normalization of
protein content in eachwell, BCA protein assaywas performedwith the
same 96 well plate and all ﬂuorescence data were normalized to μg of
protein. The differences in ﬂuorescence intensities between resistant
and sensitive cells were analyzed using t-test of signiﬁcance. Data are
shown in Fig. 3.2.3. Protein expression in insect cells
High Five™ insect cells were seeded in culture ﬂasks with Insect-
XPRESS media and cultured at 27 °C. After a few passages, cells were
counted by CASY1 Model TT and 18.6 Mio cells per T175 ﬂask wereMDCK sensitive
MDCK sensitive cells observed by confocal microscopy.
Fig. 3.Measurement of accumulation of 3-methoxyﬂavones. The ﬂuorescence of accumulated compounds inMDCK BCRP andMDCK sensitive cells wasmeasured using amicroplate read-
er and thedatawere normalized to theprotein content in eachwell as calculated byBCAprotein estimation assay. Cellswithout compoundwereused as negative control. Data is expressed
as mean ± SD of three independent experiments (NS: not signiﬁcant, *p b 0.05, **p b 0.01, t-test of signiﬁcance). # Compound 6 showed very low ﬂuorescence.
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californica multicapsid nuclear polyhedrosis virus (AcMNPV). 90 h
after infection, when cells were swollen, they were harvested. Cell
pellets were centrifuged and afterwards membrane preparation was
performed. 2 ml of membrane preparation homogenization buffer
(50 mM Tris pH 7.5, 2 mM EGTA pH 7.0, 50 mMMannitol, 2 mM DTT,
1 mM PMSF, 2 μM pepstatin, 1 μM leupeptin, 1 mM benzamidine) was
used for 20million cells. Cellswere disrupted by a dounce homogenizer.
Cellular debris was pelleted by centrifugation at 500 ×g for 10 min at
4 °C and was discarded. The supernatant was ultracentrifuged at
300,000 ×g for 30 min at 4 °C to obtain a pellet of enriched plasma
membranes. Finally membranes were resuspended in 100 μl resuspen-
sion buffer (50mMTris pH7.5, 1mMEGTA at pH 7.0, 10% (v/v) glycerol,
0.3Mmannitol, 1mMDTT, 1mMPMSF, 2 μMpepstatin, 1 μM leupeptin,
1 mM benzamidine) per ﬂask and were frozen and stored at−80 °C.
ATPase activity of ABCG2 in membranes of High Five insect cells was
measured by a colorimetric ascorbic acid ammonia molybdate reaction
described below.
2.4. SDS gel-electrophoresis and western blot analysis
After membrane preparation of High Five insect cells, it was neces-
sary to check the presence of ABCG2 protein in themembranes. To con-
ﬁrm this, we ﬁrst performed an amido black protein assay to determine
the content of protein present in the membrane preparation. After-
wards 10 μg total proteinwas loadedonto each lane of a 4–15%Criterion
TGX gel from BioRad, separated by electrophoresis and then electro-
transferred onto nitrocellulose membranes. Positive control of ABCG2
as well as negative control of High Five insect cell membrane prepara-
tions not infectedwithABCG2 baculoviruswere also run for veriﬁcation.
The nitrocellulose membranes were blocked in 5% nonfat dry milk
dissolved in TBS-T (Tris-buffered saline with tween 20). For determin-
ingABCG2 expression, blotswere probedwith themonoclonal antibody
BXP-21 (Abcam, Cambridge, UK), which is a speciﬁc anti-BCRP anti-
body. As a secondary antibody, goat anti-mouse IgG HRP conjugate
(H+L)-antibody (MerckMillipore, Darmstadt, Germany) was used.
The immunocomplex was visualized with Thermoscientiﬁc Pierce
Chemiluminescence ECL reagent. Results obtained by western blot
analysis are shown in Fig. 4.
2.5. ATPase activity measurements
For testing the functionality of ABC transporter protein, it is necessary
to determine the ATPase activity of the membrane preparation. For this
purpose, membranes were analyzed using vanadate-sensitive basaland vanadate-sensitive drug-stimulated ATP hydrolysis. 10–15 μg total
membrane protein was incubated in 100 μl assay buffer (50 mM Tris
pH 7.5, 2 mM EGTA pH 7.0, 5 mM sodium azide, 1 mM oubain, 2 mM
DTT, 50 mM KCl, 10 mMMgCl2) in the presence or absence of 300 μM
vanadate. The ATPase reaction was started by the addition of 5 mM
ATP and all samples were incubated for 30 min at 37 °C. 25 μMprazosin
and in a fewexperiments 25 μMquercetinwere used as standard. The re-
actionwas stoppedby the additionof 100μl of 5% SDSafter 30min. The col-
orimetric detection was performed afterwards by the addition of 400 μL Pi
reagent (1% ammoniummolybdate, 0.014%antimonypotassium tartrate in
2.5N sulfuric acid), 500 μl H2O and 200 μL 1% ascorbic acid solution [23]. All
samples were incubated for 10 min at room temperature and optical den-
sitywas determined at 880 nm [24]. To calculate the content of liberated Pi,
standard curves were generated using Na2HPO4.
After ensuring that the ABCG2 proteinwas functionally active, it was
further used to investigate ATPase activity of test compounds to deter-
minewhether they stimulate ATPase activity pointing to possible trans-
port by ABCG2. The investigated compounds were dissolved in DMSO,
ensuring that the ﬁnal concentration of DMSO in the assay medium
was not higher than 1%. Control experiments indicated that DMSO at
this concentration had no observable effect on the ATPase activity. All
assays were repeated at least three times and performed in triplicates.2.6. MTT cytotoxicity assay
Intrinsic cytotoxicity of most promising inhibitory compounds 1, 3,
4, and 6 was determined in MDCK BCRP and MDCK sensitive cells
using theMTT cytotoxicity assay. The assaywas performed as described
earlierwithminormodiﬁcations [21,25]. Cells were seeded into 96-well
tissue culture plates (Sarstedt, Newton, USA) at a density of 2500 cells
per well in a volume of 180 μl and kept under 5% CO2 at 37 °C for 6 h.
Attachment of cells was controlled under the microscope and 20 μl of
the test compoundswere added to achieve the requiredﬁnal concentra-
tion in a volume of 200 μl. Control experiments were performed with
medium containing 10% (v/v) of DMSO (positive control) and only
medium (negative control). Also, dilution solvent (medium) containing
the same amount of methanol (2% in highest concentration) in each
dilution was studied for its effect on cell viability. After an incubation
period of 72 h, theMTT reagentwas added (20 μl of a 5 mg/ml solution)
to each well. Plates were further incubated for 1 h and then the assay
was terminated by removing supernatants and lysing the cells with
100 μl DMSO per well. Viability of cells was determined spectrophoto-
metrically by measuring absorbance at 570 nm and background correc-
tion at 690 nm using a Thermo Scientiﬁc Multiskan® EX microplate
reader.
Fig. 4. Characterization of High Five membranes for the overexpression of ABCG2. Mem-
brane protein preparations (10 μg) of High Five insect cells were electrophoretically sep-
arated and transferred to nitrocellulose membrane. Western blots were probed with a
speciﬁc antibody against ABCG2 (BXP-21). Lane 1 shows positive control of ABCG2, lane
2 shows membrane protein preparations of High Five insect cells infected with ABCG2
baculovirus and lane 3 shows negative control of High Five insect cell membrane prepara-
tions not infected with ABCG2 baculovirus.
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resistance reversal ability of test compounds 1, 3, 4 and 6. Final concen-
trations of test compounds were selected based on the IC50 values
obtained in Hoechst 33342 assay. For compounds 1 and 3 ﬁnal concen-
trations of 1 μM and 5 μMwere investigated. For compound 4 1 μM and
2.2 μM and for compound 6 0.5 μM and 1.8 μM were used as it is the
most potent inhibitor in the data set. For this purpose SN-38 (the active
metabolite of irinotecan and a substrate of ABCG2) was selected as an
anti-cancer chemotherapeutic agent, and the effect of the test com-
pounds on the cytotoxicity of SN-38 in ABCG2 overexpressing MDCK
cells was studied.
2.7. Inhibition kinetics
To gain more detailed information about the type of interaction of
pentamethyl quercetin (compound 4) towards Hoechst 33342 and
pheophorbide A, we performed extended enzyme kinetic experiments.
Within this study we used various concentrations of compound 4 as
well as of Hoechst 33342 or pheophorbide A respectively. For data anal-
ysis we utilized the Lineweaver-Burk linearization technique, which
enabled us to determine the type of interaction between compound 4
and Hoechst 33342 or pheophorbide A.
The Hoechst 33342 assay was performed as described previously
with minor modiﬁcations [21]. The concentration of Hoechst 33342
varied in the range of 0.8 μM to 2.0 μM, whereas the concentration of
compound 4 varied between 0.0562 μM and 0.562 μM. Response in
absence of compound 4 was used as control. Fluorescence was mea-
sured immediately after the addition of Hoechst 33342 in constant
intervals of 60 s up to 120 min at an excitation wavelength of 355 nm
and an emission wavelength of 460 nm, using a 37 °C tempered BMG
POLARstar microplate reader.
The pheophorbide A assaywas also performed as described previous-
ly withminor modiﬁcations [21]. After adding increasing concentrations
of compound 4, pheophorbide A was added in various concentrations
(0.2 μM, 0.6 μM, 1.0 μM, 1.4 μM, 1.8 μM). After 120 min of incubation
with the ﬂuorescent dye, ﬂow cytometry detection was performed
using FACS Calibur (Becton Dickinson, Heidelberg, Germany). Pheophor-
bide A was excited at the wavelength of 488 nm, and emission was de-
tected in the FL3 channel (670 nm).
3. Results and discussion
3.1. Investigation of selected compounds for their accumulation in ABCG2
overexpressing cells
It was observed thatmost of the ﬂavonoids bearing a 3-methoxy sub-
stituent showmoderate to strongﬂuorescence at an excitation of 355 nm
and emission at 460 nm. The ﬂuorescence property of these compounds
at the wavelength of the DAPI ﬁlter (excitation λ= 358 nm, emission
λ= 461 nm) made it possible to investigate their accumulation in cells
using confocal microscopy. For this purpose, we decided to investigate
compounds 4 and 5 for their accumulation in ABCG2 overexpressing
cells with the aid of confocal microscopy. Samples were prepared by in-
cubating test compounds at 25 μM ﬁnal concentration for 4 h. Prepared
sampleswere visualized at DAPI ﬁlter using Nikon A1 confocal microsco-
py system. As it canbe seen in Fig. 2, compound4 showeddecreasedﬂuo-
rescence in ABCG2 overexpresing MDCK BCRP cells when compared to
MDCK sensitive cells. No such effect was observed for compound 5.
To quantify the accumulation ﬂuorescence of all the test compounds,
a microplate reader was used. For this purpose, samples were prepared
by seeding cells in 96-well plates and incubating them with 25 μM of
test compounds for 4 h in incubator maintained at 37 °C. After washing
cells several timeswith cold buffer,ﬂuorescencewasmeasured at an ex-
citationwavelength of 355 nmand emissionwavelength of 460 nm. The
ﬂuorescence data were normalized to protein content in each well to
correct for any cell loss in the washing steps. Fig. 3 shows theﬂuorescence per μg total protein content for all test compounds. It can
be seen that almost all compounds showed reduced accumulation in
ABCG2 overexpressing MDCK BCRP cells when compared to the corre-
sponding sensitiveMDCK cells. Hoechst 33342was used as positive con-
trol, which is a known ABCG2 substrate, showing ﬂuorescence at the
same excitation and emission wavelengths. As it can be seen from
Fig. 3, Hoechst 33342 showed highly reduced accumulation in ABCG2
overexpressing cells. Except compound 5, all compounds showedmod-
erate to high reduction in accumulation in ABCG2 overexpressing cells.
These results suggest that compounds 1–4 and 6–7 could be substrates
of ABCG2 resulting in their efﬂux and hence lower accumulation. To
conﬁrm this effect, we further investigated these compounds in ATPase
assay using ABCG2 membrane preparations from High Five insect cells.3.2. ABCG2 membrane preparation and ATPase assay
In insect cells there is a very high overexpression of target proteins,
which means a big advantage over some other protein expression
systems. This system is useful for both, studies in crude membrane
vesicles from infected cells and for further puriﬁcation and reconstitu-
tion of active transporters and afterwards studies of transporter
proteins [26]. For studying ATPase activity of test compounds, puriﬁca-
tion of transporter protein is not necessary, because there are no other
ATPases in the membranes of insect cells.
In our experiments, ABCG2 overexpression was generally maximal
90 h after infection with baculovirus. Functional overexpression of
active ABC transport proteins in insect cells has provided new insights
into the ATPase activities of the multidrug transporter. The use of
crude plasma membrane prepared from BV-ABCG2 infected High Five
cells, has been demonstrated to possess BCRP-associated, substrate
stimulated ATPase activity [26].
The crude membrane ATPase assay described was used by several
laboratories to screen potential ABCG2 substrates, based on the relative-
ly stringent substrate-dependence of ABCG2 ATPase activity [26]. In
Fig. 5 the vanadate-sensitive ATPase activity measurements of our test
compounds in comparison to the standards prazosin and quercetin are
depicted. All compounds were tested at a concentration of 25 μM. As it
can be seen in Fig. 5, compounds 1–4 show nearly the same effects as
the standards, whereas compound 5 show very low ATPase activity
Fig. 5.ATPase activity of compounds 1–7measured using High Five insect cellmembranes. ATPase activity of all compoundswasmeasured at 25 μMconcentration. Prazosin and quercetin
were used as positive controls, while the inhibitory effect of Ko143 was used as negative control. All data are expressed as vanadate-sensitive ATPase activity.
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than the basal activity. Compound 6 and 7 showed a moderate ATPase
activity when compared to that of prazosin.
The results obtained for compounds 4 and 5 in the confocal mi-
croscopy are consistent with ATPase activity data, where the accu-
mulation of compound 4 in ABCG2 overexpressing cells was lower
than in sensitive cells, while compound 5 showed no decrease in
the accumulation. From the results obtained in confocal microscopy
and ATPase activity measurements, it can be suggested that com-
pound 4 is a substrate of ABCG2. Although it is proposed to be a sub-
strate of ABCG2, this compound was found to be also an inhibitor of
ABCG2. In earlier studies we performed functional assays such as
Hoechst 33342 (see Table 1) and pheophorbide A accumulation as-
says, in which compound 4 showed good inhibition potencies. It
seems that it inhibits drug transport in a non-competitive manner
towards Hoechst 33342, so it has to bind at a different binding posi-
tion, see Fig. 10.
All compounds showing substantial ATPase activity were further in-
vestigated at increasing concentrations to obtain concentration response
curves and the results obtained are depicted in Fig. 6. Compound 1which
has only a 3-methoxy substitution on the ﬂavone scaffold, showed a
“bell-shaped” curve which is typical for substrates having close relative
afﬁnities for two distinct binding sites [27,28]. It is assumed that the
transporter contains two distinct binding sites for substrates. One of
the binding sites has a high afﬁnity towards the substrate and is ac-
tivating/transporting, which is postulated to be localized in the cy-
toplasmic or transmembrane domains. The other one has low
afﬁnity towards the substrate and is inhibiting, this is located in
the extracellular domains [16,17]. This suggests that the inhibitory
effect observed at higher concentrations (second part of the curve)
is believed to be due to a secondary, lower afﬁnity binding site in
the extracellular part of the transporter. If the afﬁnities to both
binding sites are close to each other, it results in a bell-shaped
curve. If the afﬁnity to the activating binding site is much higher
than for the inhibitory site, a Michaelis–Menten type curve will be
observed as only the activating site is targeted.
Compounds 2–4 showed typical Michaelis–Menten curves, where
there was an increase in the ATPase activity with increasing compound
concentration. These compounds bind at the high afﬁnity binding site in
the transmembrane or cytoplasmic regions of the transporter. Among
these compounds compound 3 showed lower ATPase activity at higher
concentration when compared to compounds 2 and 4. As it can be seen
by comparison of concentration response curves for compound 4 and
prazosin (a well-known ABCG2 substrate), compound 4 leads to an ap-
proximately 1.5 fold higher stimulation than prazosin. The combination
of compound 4 and prazosin (1:1) suggests that both bind at different
binding positions because of the bell-shaped curve. In the beginning,
at lower concentrations, it can be seen that binding takes place at thehigh afﬁnity binding site producing an activating and at high concentra-
tions it produces an inhibitory effect.
Compound 5 showed nearly no stimulation of ATPase activity in the
ATPase assay, suggesting its non-substrate nature. This observation is in
accordancewith the results obtained in accumulation studies using con-
focal microscopy and ﬂuorescence measurement. In these studies no
substantial efﬂux of compound 5 was observed. Due to its very low
ATPase activity, it was not possible to generate any ATPase concentra-
tion response curves.
The last two compounds 6 and 7 are different from the other inves-
tigated compounds in the respect that they bear anOH group at position
5 of the ﬂavone scaffold. In earlier studies, presence of OH at position 5
has been shown to be important for ABCG2 inhibition. From Fig. 6 it can
be seen that compound 6 shows a Michaelis–Menten inhibitory curve,
while compound 7 produced a bell shaped-curve. Compound 6, which
is the most potent inhibitor in the series (see Table 1) showed very
slight decrease in the accumulation in ABCG2 overexpressing cells, but
due to its very low ﬂuorescence this data is not conclusive. From the
ATPase activity curve it can be seen that at low concentrations it showed
rather high stimulation of ATPase activity, suggesting that it binds to the
high afﬁnity activating site of the transporter. On the other hand at
higher concentrations it was able to lower the ATPase activity, suggest-
ing that the afﬁnities for the activating and inhibitory site are relatively
close to each other. Among all tested compounds it was themost potent
inhibitor, which may explain this phenomenon.
The effect of Ko143, a potent inhibitor of ABCG2, on theATPase activ-
ity of compound 4 (25 μM) is depicted in Fig. 7. Due to inhibitory effect
of Ko143 on ABCG2, it produced a Michaelis–Menten inhibitory curve.
As it can be seen, higher concentrations of Ko143 were able to decrease
the ATPase activity of 25 μM of compound 4.
3.3. Cell viability assay
After discovering that at least one of the 3-methoxy ﬂavones which
have been shown to be inhibitors of ABCG2 in functional assays are also
substrates of ABCG2, we decided to carry out in vitro cell viability assays
using sensitive and ABCG2 overexpressing cells, to investigate this
further. Generally, for cytotoxic compounds which are substrates of
ABCG2, there is a difference in cytotoxicity in sensitive and resistant
cells. Hence, if test compounds are cytotoxic and show lower cytotoxic-
ity in resistant cells than in the sensitive cells, we could conclude that
these compounds are being transported by ABCG2 leading to lesser
intracellular accumulation and lower toxicity.
For this purpose, we carried out cell viability assays for compounds
1, 3, 4 and 6 by using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltet-
razolium bromide (MTT) colorimetric assay. The toxicity studies of
these compounds were performed using MDCK BCRP and sensitive
MDCK cells. The concentration–response curves obtained inMTT assays
Compound 1 Compound 2
Compound 3 Compound 4 vs. prazosin
Compound 4+  prazosin (1:1) Compound 6 
Compound 7
Fig. 6. Concentration response curves for compounds 1–7 in the ATPase assay. High Five insect cell ABCG2membrane preparations were used for carrying out ATPase activity measurements.
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Fig. 7. Effect of Ko143 on ATPase activity in the presence of compound 4. Effect of increas-
ing concentration of ABCG2 inhibitor Ko143 on theATPase activity of compound 4 (25 μM)
was studied.
2936 J. Gallus et al. / Biochimica et Biophysica Acta 1838 (2014) 2929–2938for compounds 1, 3, 4 and 6 are shown in Fig. 8. It can be seen that all
four compounds investigated showed very low cytotoxicity. These com-
pounds showed a decrease in cell viability only at very high concentra-
tions. Due to their low cytotoxicity a substantial difference in
cytotoxicity in sensitive and resistant cells was not observed. Com-
pound 4 that is supposed to be a substrate was even slightly more
toxic against the MDCK BCRP cells than against sensitive MDCK cells
(Fig. 8). Hence, it is not possible to conclude about the substrate nature
of these compounds based on their cytotoxicity.
We also investigated these ABCG2 inhibitors if they have the ability
to overcome drug resistance to another cytotoxic ABCG2 substrate inCompound 1
Compound 4
Fig. 8. Cytotoxicity of selected test compounds in MDCK cells. Cytotoxicity of selected test
cells. Compounds 1, 3, 4 and 6were investigated up to 100 μMconcentration for 72 h. Closed tri
(medium) containing 2% methanol in the highest concentration.ABCG2 overexpressing cells. For this purpose test compounds 1, 3, 4
and 6, which showed highest ABCG2 inhibition in Hoechst 33342 and
pheophorbide A accumulation assays, were investigated for their ability
to reverse resistance towards SN-38 in MDCK BCRP cells. Compounds 1
and 3were investigated at ﬁnal concentrations of 1 μM and 5 μM, com-
pound 4 at ﬁnal concentrations of 1 μM and 2.2 μM and compound 6 at
ﬁnal concentrations of 0.5 μM and 1.8 μM. Fig. 9 depicts the shift in the
dose–response curves to SN-38 in MDCK BCRP cells in presence of the
test compounds. This shift in dose–response curves towards lower con-
centrations indicates sensitization of MDCK BCRP cells to cytotoxicity of
SN-38. All the compounds were able to signiﬁcantly reverse the resis-
tance even at low micromolar concentrations and a complete reversal
of resistance was observed at higher concentrations selected for each
compound.
3.4. Inhibition kinetics
To getmore detailed information related to the type of interaction of
selected ﬂavonoids with ABCG2 in the presence of other substrates, we
performed enzyme kinetic studies with compound 4. This compound
was found to have a substrate nature in microscopy studies as well as
in ATPase activity studies. In enzyme kinetic experiments we varied
both, the concentrations of Hoechst 33342 and compound 4, as well as
the concentrations of pheophorbide A and compound 4. The enzyme
kinetics data obtained allowed us to determine the type of interaction
between the compound 4 and Hoechst 33342 or pheophorbide A
through application of the Lineweaver–Burk linearization technique.
The obtained Lineweaver–Burk plots for both kinetic binding studies
are depicted in Figs. 10 and 11.Compound 3
Compound 6
compounds was determined in the MTT assay using MDCK BCRP and sensitive MDCK
angle:MDCK BCRP cells, closed circle: MDCK sensitive cells and open circle: dilution solvent
Compound 1 Compound 3
Compound 4 Compound 6
Fig. 9. Effect of test compounds on cytotoxicity of SN-38 in ABCG2 overexpressing cells. Dose–response curves of SN-38 cytotoxicity. The effect of compounds 1, 3, 4 and 6 on SN-38 cy-
totoxicity inMDCK cells is shown. Concentrations of test compoundswere selected according to their inhibitory potencies. Compounds 1 and 3were investigated at 1 μM(open triangles)
and 5 μM(open circles) ﬁnal concentrations. Compound 4was investigated at 1 μM(open triangles) and 2.2 μM(open circles) ﬁnal concentrations. Compound 6was investigated at 0.5 μM
(open triangles) and 1.8 μM(open circles)ﬁnal concentrations. ABCG2 overexpressingMDCKcellswithout inhibitor (closed squares) showed less sensitivity towards SN-38, than sensitive
MDCK cells (closed circles).
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concentrations due to overlapping ﬂuorescence of Hoechst 33342 and
compound 4. Therefore concentrations selected for the compound 4
were restricted to a lower range where the ﬂuorescence of the com-
pound 4 was not dominating. Maximum inhibition was inferred from
the Hoechst 33342 ﬂuorescence in presence of the non-ﬂuorescent
ABCG2 inhibitor Ko143. From Fig. 10, it can be suggested that there is
a non-competitive interaction between compound 4 and Hoechst
33342, indicating that it binds at a distinct site on ABCG2 than that of
Hoechst 33342. Similar resultswere obtained for enzymekinetic studies
carried out using pheophorbide A, where a non-competitive interaction
was also observed between pheophorbide A and compound 4. Here, no
interference between the ﬂuorescence of the ﬂavonoid with ﬂuores-
cence of pheophorbide A was observed.Fig. 10. Interaction of compound 4 with Hoechst 33342. Lineweaver–Burk plots for com-
pound 4 showing a non-competitive interaction type with Hoechst 33342. Control
(open circle), 0.0562 μM (closed circle), 0.1 μM (open square), 0.178 μM (closed square),
0.316 μM (open triangle), 0.562 μM (closed triangle).4. Conclusions and summary
In the current study we investigated several ﬂuorescent 3-methoxy
ﬂavones for their substrate nature by ABCG2. These compounds were
previously found to be good inhibitors of ABCG2. From the current
study, we can conclude that all selected compounds except compound
5 and 6 seem to be substrates of ABCG2, although they are inhibitors
of ABCG2 as identiﬁed in Hoechst 33342 and pheophorbide A accumu-
lation assays. Compounds 1 and 7 produced bell-shaped ATPase activity
curves,which is characteristic for typical membrane active transporters,
whose transport site alternates between high and low afﬁnity state [29].
Compound 6 showed activation at very low concentrationswhile produc-
ing inhibitory effect at higher concentrations. Compounds 2–4 producedFig. 11. Interaction of compound 4 with pheophorbide A. Lineweaver–Burk plots for com-
pound 4 showing a non-competitive interaction typewith pheophorbide A. Control (open
circle), 0.1 μM (closed circle), 0.316 μM (open square), 0.562 μM (closed square), 1.0 μM
(open triangle), 1.78 μM (closed triangle).
2938 J. Gallus et al. / Biochimica et Biophysica Acta 1838 (2014) 2929–2938activating Michaelis–Menten ATPase activity curves and showed less ac-
cumulation in ABCG2 overexpressing MDCK BCRP cells in comparison to
sensitive cells, which suggests that they were transported by ABCG2.
Compound 4 being ﬂuorescent and the strongest inhibitor of ABCG2
in this examination set after compound 6 (which showed no substrate
nature of ABCG2), we decided to carry out extensive studies with this
pentamethoxy ﬂavone. Lower accumulation of this compound in
ABCG2 overexpressingMDCK BCRP cells when compared to its accumu-
lation in non ABCG2 overexpressing sensitive cells was conﬁrmed by
confocal microscopy studies. In ATPase activity studies it showed an ap-
proximately 1.5 fold higher stimulation of ATPase activity in comparison
to prazosin, a well-known substrate of ABCG2. The combination of com-
pound 4 and prazosin (1:1) resulted in a bell-shaped ATPase activity
curve, which suggests different binding positions of these two com-
pounds. Interaction of compound 4 with prazosin by enzyme kinetic
studies could not be veriﬁed due to experimental limitations. At lower
concentrations, it can be seen that binding takes place at the high afﬁn-
ity binding site producing an activating and at high concentrations it
produces an inhibitory effect. We were also able to show the inhibition
of Ko143 on the ATPase activity of selected compound 4.
In cell viability assay, compound 4 was found to have low toxicity
even in the higher micro-molar range and was able to reverse the
drug resistance for SN-38 in ABCG2 overexpressing cells. In enzyme ki-
netic studies of compound 4, we were able to show a non-competitive
interaction of compound 4 towards Hoechst 33342 as well as towards
pheophorbide A. From these observations it can be suggested that, al-
though 3-methoxy ﬂavones are good inhibitors of ABCG2, they are
also substrates and their inhibitory activity could be due to their fast
diffusion.Acknowledgment
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